



Teva's Position on Health Equity and Access to Medicines

January 2026



Our purpose is clear – **We are all in for better health**. We are committed to improving the lives of patients worldwide by making medicines accessible to those who need them most. As a global biopharmaceutical leader, we recognize that increasing access to quality medicines is fundamental to improving health outcomes and achieving our business objectives. While our generic and biosimilar medicines enable millions of people across the world to access quality and more affordable medicines, our innovative medicines provide treatments for unmet health needs, with specific access considerations incorporated early on, during medicine research and development.

At Teva Pharmaceutical Industries Ltd (hereinafter “Teva”), our commitment to health equity and access is embedded in our Sustainability strategy and guides our approach, which is grounded in the core principle that every individual – regardless of geography or circumstance – deserves access to essential medicines. While the global demand for medicines continues to rise¹, significant barriers – which range from supply chain complexities to health system limitations and affordability challenges – persist, particularly in under-resourced settings. Addressing these challenges requires collaboration from industries, governments, and local partners across the healthcare ecosystem.

Access to medicines needs to be grounded in the principles of availability, accessibility, and affordability which are essential to overcoming the barriers to access. Providing this access is central to who we are at Teva. This is demonstrated by our significant geographical footprint, our broad portfolio of medicines across a vast range of therapeutic areas, and our world-class expertise.

Teva's Health Equity and Access to Medicines strategy is closely aligned with our Pivot to Growth strategy – in particular, the Stepping up Innovation and Sustaining our Generic Powerhouse pillars. This integrates access objectives with commercial priorities to ensure positive social impact and sustainable business growth.

Health Equity and Access to Medicines forms a core pillar of our Healthy Future Sustainability strategy and sets transparent access targets to demonstrate our commitment. It also guides our commitment to advancing health equity by prioritizing the needs of underserved populations and striving to address disparities in healthcare access.

Teva takes a strategic and proactive approach to Health Equity and Access to Medicines. This is exhibited through: supplying quality and affordable generic medicines to millions of patients across the globe each day; providing medicines to underserved populations; addressing emergencies and disasters quickly and efficiently; strengthening healthcare systems and building local capacity to improve health systems and services; increasing access to our products in low- and middle-income countries (LMICs) through product registration submissions; and including access considerations, such as a patient-centric approach, within our product development.

We are committed to building partnerships rooted in a deep understanding of local needs, shared goals, and the amplification of positive impacts. Through these partnerships and targeted programs, we strive to expand access

¹ <https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-outlook-through-2029>

to essential medicines, support public health goals, and promote better health outcomes for underserved populations.

The scope of this position applies to all companies owned and operated by Teva. Our organization, including all directors, executives, employees, and subsidiary and affiliated companies, is committed to applying our expertise and resources to improve health equity and advance access to quality medicine for people across the world.

This position covers different themes related to Health Equity and Access to Medicines, including actual and potential impacts, risks, and opportunities for Teva.

Our Health Equity and Access to Medicines Aspirations, Approach and Commitments

Innovating to Improve Access

We believe that innovation must serve the needs of both patients and the wider society. This includes a deep consideration of unmet global health needs. Our approach to research and development is therefore anchored in the principle of patient-centricity, which ensures our innovations address real-world health challenges and promote inclusivity.

Our world-class expertise reflects our ability to operate across the full spectrum of innovation to continuously improve health worldwide. We do this by:

- Creating the medicines needed both for today and for the future.
- Driving the discovery and development of modern therapies.
- Innovating throughout our established portfolio and promising pipeline.
- Nurturing and strengthening innovation ecosystems.
- Leveraging strategic partnerships to accelerate the development and supply of therapies.

Patient-centricity means putting patients at the center of everything we do, and we believe this is fundamental during clinical research. We uphold the principle that all individuals, as appropriate, regardless of background or circumstance, should have the opportunity to participate in and benefit from medical innovation.

Our commitment to inclusivity, transparency, and collaboration ensures that diverse perspectives inform our research. This drives the development of medicines that most effectively address unmet patient needs. Breaking down barriers, such as remote participation to tackle mobility constraints, encourages underrepresented groups to participate in clinical trials. Collaborating with patients, caregivers, and advocacy organizations during clinical development and its study design fosters meaningful dialogue that enriches trials with real-world insights.

Engaging in development efforts for additional indications, reformulation activities and/or introduction of delivery systems further broadens the reach and impact of our medicines.

Enhancing Accessibility by Offering Cost-Effective Generic Medications for All

Our affordable medicines reach millions of patients each day, enabling us to increase our support for underserved communities. This affordability is essential to access, and we are committed to providing high-quality, cost-effective medicines that enable health systems and patients to benefit from sustainable healthcare solutions.

Our generic and biosimilar medicines generate tens of billions of U.S. dollars in annual savings for healthcare systems² — including governments, payers, and patients. These savings enable governments to allocate additional resources toward healthcare provision and ease the financial burden on families by reducing out-of-pocket costs for essential medicines. They also increase access to medicines on the WHO Essential Medicines List (EML), underscoring our critical role in the global effort to improve access to medicines.

Our development and launch of generic and biosimilar medicines, along with our vast footprint, including in LMIC markets, enhances our global presence. Where possible, we engage early with governments, healthcare service organizations, and/or non-governmental organizations to establish frameworks for medicines to reach local patients at sustainable costs.

Harnessing our Portfolio to Tackle Unmet Needs and Increase Impact

At Teva, we are guided by the principle that access to essential medicines is imperative. We are committed to maximizing our positive impact by prioritizing those most in need, especially underserved populations. Our approach is rooted in the belief that strategic, sustainable access initiatives are essential to advancing health equity.

We aspire to create meaningful and measurable improvements in patient outcomes by:

- Upholding the principles of health equity in all access initiatives by focusing on underserved populations.
- Ensuring our efforts are guided by ambitious, transparent goals and a commitment to continuous improvement.
- Focusing on strategic, targeted, multi-year programs designed and developed in partnership with trusted organizations.
- Collaborating with trusted partners to reach communities that would otherwise lack access to life-saving and life-changing medicines.
- Striving for long-term sustainability by integrating access considerations into our core business strategy and decision-making.

² <https://www.tevapharm.com/globalassets/tevapharm-vision-files/teva-esg-progress-report-disclosures-2024.pdf>

- Understanding that our responsibility extends beyond product provision to fostering resilient systems that enable ongoing access for those who need it most.

Teva takes a systematic approach to initiating, developing and implementing access programs. This ensures that we have standardized processes in place to address different access needs. Our careful and compliant processes are aligned with all relevant business units and its aims include:

- Guaranteeing access programming is integrated into our commercial operations.
- Ensuring maximum efficiency and prioritization of access initiatives.
- Enabling the supply for such programs.
- Creating a more sustainable impact over time.
- Providing a framework through which to identify additional access opportunities.

Donations, social business ventures, and Global Health Tenders provide a multitude of opportunities for increased patient reach and expanded impact, through partnerships with reputable organizations to ensure delivery and implementation.

Strengthening Healthcare Systems

Teva recognizes that true health equity cannot be achieved without strong, resilient healthcare systems, and we see supporting the development and strengthening of healthcare systems as a core pillar of our access strategy. We believe that improving access to medicines requires a holistic approach – one that addresses not only the availability of treatments, but also the broader determinants of health, including financial, geographic, socioeconomic, cultural, and other factors.

Our guiding principles include:

- Partnering with organizations that share our commitment to community-driven, sustainable solutions.
- Promoting health literacy, capacity building, and empowerment of local healthcare providers and leaders.
- Supporting the development of infrastructure in under-resourced areas, recognizing that resilient systems are essential for equitable access to medicines and improved health outcomes.
- Advocating for the integration of social, economic, and environmental considerations into health system strengthening.
- Driving the advancement of both health equity and environmental stewardship, through the integration of solutions at the nexus of health and environment.

We believe that by fostering robust healthcare systems, we can help create the conditions necessary for equitable access to care and improved health outcomes for all. This goes for increasing local capacity – by training healthcare providers and community leaders, and providing digital training tools and resources; engaging with patients through health promotion activities in rural areas; raising health awareness among community and religious

leaders; and bringing screening and diagnostics into hard-to-reach communities – as well as for improving infrastructure, storage, and cold chain abilities. Such initiatives help improve healthcare systems and capacity, enhance health literacy and awareness, increase treatment accessibility through diagnosis and screening, and build trust within local communities.

Increasing our Footprint to Reach more Underserved Populations

In order to expand access to our medicines in the most hard-to-reach places, we are deliberate in expanding our product submission and registration in LMICs. This demonstrates how important access is to Teva's core business. Our commitment to increase product submissions for a specifically selected pool of products, representing some of the largest unmet needs with the greatest growing burden of disease, supports our systematic approach.

Partnering to Advance Global Health

We are conscious that improving health equity and access to medicines in a sustainable and holistic manner can only be achieved in collaboration with others. We therefore seek partnerships to advance global health solutions and capacity building programs.

We engage with non-governmental organizations, industry alliances, foundations, healthcare institutions, technology partners, and others to enhance access to medicines and mitigate barriers. We also regularly engage with healthcare organizations and industry partners to advance public policy that creates better patient outcomes. As a member of leading industry associations, collaborative think tanks, and cross-sector forums around the world, we share our expertise and explore ways to improve healthcare together.

Our strategic community partners maintain direct and close contact with patients across various programs, providing us with a comprehensive understanding of on-the-ground needs. Additionally, our partners manage, oversee, and monitor field activities, providing us with insights into evolving needs, lessons learned, and progress toward shared objectives.

Compliance-Driven Access to Medicines

Teva is committed to responsible and ethical engagement with partners, governments, healthcare providers, patients, and communities to ensure sustainable and equitable access to medicines across all programs and initiatives.

This commitment is upheld through strict compliance and ethics controls that govern our interactions, and is guided by applicable laws, regulations, and Teva's internal policies and Code of Conduct. We continuously monitor and enhance these controls to ensure transparency, accountability, and to prevent misconduct – safeguarding stakeholder trust and promoting responsible access to medicines.

Governance Structure for Access to Medicines Management

Our Health Equity and Access to Medicines initiatives are approved by the responsible Executive Managers and reviewed by the Board of Director's Compliance Committee. We have a dedicated Health Equity and Access to Medicines Steering Committee, which is chaired by the Senior Vice President, Global Head of Sustainability and includes the participation of other senior managers.

The Committee advises on and oversees our Access to Medicines initiatives on a strategic level. Additionally, Teva's Access activities are shared with the Sustainability Steering Committee chaired by the Chief Executive Officer. Our Access to Medicines targets are also part of the Executive Management variable remuneration.

Our Access Hub is comprised of representatives from across Teva's business units, providing a holistic perspective on our activities. This group is responsible for planning and implementing programs on an operational level and consists of representative leads from key business units. It is overseen by Teva's Global Head of Health Equity and Access to Medicines.

Reporting

We review our Health Equity and Access to Medicines performance on a quarterly basis with our Executive Management and Board of Directors. We are committed to reporting transparently on our access targets, actions and programs in our annual [Healthy Future Report](#) and accompanying disclosures.

Application of this Position

This position is approved by the responsible Teva management members and endorsed by all Executive Management. We communicate this position to our employees and publicly on our website.